Mergers and Acquisitions TRANSACTIONAL

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions in both the United States and Europe.

Market leaders in life sciences, technology, financial services, communications and many other industries turn to WilmerHale for legal advice and business advantage. In 2013, we advised clients throughout the United States and Europe on more than 75 M&A transactions, providing guidance in areas including corporate, securities, antitrust and tax. Since 2004, we have participated in more than 1,000 mergers and acquisitions with a total value in excess of $350 billion, ranging from sales of VC-backed companies to multibillion-dollar global mergers. Our experience ranges from public-public M&A transactions and the related disclosure and fiduciary duty issues to the unique issues presented by acquisitions of financial sponsor-backed private companies. We also advise clients on hostile transactions and activist investors, and represent investment banks serving as financial advisors in M&A transactions. 


Sort By
Bothwick, Jay E.

Jay E. Bothwick

Co-Chair, Mergers and Acquisitions Practice Group

+1 617 526 6526 (t)

Leibowitz, Hal J.

Hal J. Leibowitz

Co-Chair, Mergers and Acquisitions Practice Group

+1 617 526 6461 (t)

Bain, Mick

Mick Bain


+1 781 966 2027 (t)

Boot, Jeannette K.

Jeannette K. Boot


+1 212 295 6507 (t)

Borden, Mark G.

Mark G. Borden


+1 617 526 6675 (t)

Bothwick, Jay E.

Jay E. Bothwick


+1 617 526 6526 (t)

Braun, Martin

Dr. Martin Braun


+49 69 27 10 78 207 (t)

Brown, Lillian

Lillian Brown


+1 202 663 6743 (t)

Buckland, Peter

Peter Buckland


+1 650 858 6036 (t)


Our recent M&A transactions include:

  • Akamai Technologies' acquisition of Cotendo for $268 million
  • American Dental Partners' acquisition by JLL Partners for $398 million (counsel to special committee)
  • BioVex's acquisition by Amgen for $1 billion (including milestone payments)
  • Enobia Pharma's acquisition by Alexion Pharmaceuticals for $1.1 billion (including milestone payments)
  • HMS Holdings' acquisition of HealthDataInsights for $400 million
  • ISTA Pharmaceuticals' acquisition by Bausch + Lomb for $500 million
  • Kiva Systems' acquisition by Amazon for $775 million
  • Palomar Medical Technologies' acquisition by Cynosure for $294 million
  • PerkinElmer's acquisition of Caliper Life Sciences for $600 million
  • SS&C Technologies' acquisition of GlobeOp Financial Services for $900 million
  • Stromedix's acquisition by Biogen Idec for $562.5 million (including milestone payments)
  • The Medicines Company's acquisition of Incline Therapeutics for $390 million (including milestone payments)
  • The Medicines Company's acquisition of Rempex Pharmaceuticals for $474 million (including milestone payments)
  • Thermo Fisher Scientific's acquisition of One Lambda for $925 million
  • Thermo Fisher Scientific's acquisition of Phadia for €2.47 billion
  • Thermo Fisher Scientific's sale of its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare for $1.06 billion
  • TransUnion's acquisition of TLO for $154 million (bankruptcy auction)
  • Wright Express' acquisition of Fleet One Holdings for $369 million

Additional M&A experience: 2014, 20132012, 2011, 2010, 2009

Publications & News


April 2, 2014

WilmerHale Represents Alcatel-Lucent in $200M Asset Divestiture

March 3, 2014

Selected 2014 M&A Transactions

In 2013, we advised clients throughout the United States and Europe on more than 75 M&A transactions, providing guidance in areas including corporate, securities, antitrust and tax.

February 19, 2014 Survey of In-House Counsel Finds WilmerHale Among Top 20 Firms in Germany

WilmerHale has been named among the top 20 most recommended law firms in Germany by 2013/2014.

February 3, 2014

NaturalMotion Acquired by Zynga for $527 Million

On January 30, 2014, Zynga, the world's leading provider of social game services, announced its purchase of UK game-maker NaturalMotion for $527 million in cash and equity.

January 9, 2014

China’s New Anti-Corruption Policies in the Health Care Industry

January 7, 2014

WilmerHale Represents Thermo Fisher Scientific in Transaction with GE Healthcare

Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for approximately $1.06 billion.

November 1, 2013

WilmerHale Among U.S. News – Best Lawyers® “Best Law Firms” and Again Named International Arbitration “Law Firm of the Year”

The 2014 edition of the U.S. News – Best Lawyers® “Best Law Firms” list names WilmerHale as “Law Firm of the Year” in International Arbitration—this is the second consecutive year that the firm has won this honor—and honors WilmerHale as a first-tier law firm in 27 national and 60 metro-area rankings.

September 30, 2013

WilmerHale Receives “Top Tier” Ranking in 2013 Legal 500 UK

The Legal 500, the United Kingdom's guide to outstanding lawyers, has announced its annual rankings selecting WilmerHale as a top tier law firm in dispute resolution - international arbitration, and highly recommending the firm in nine other categories.

September 26, 2013

WilmerHale Receives 2013 LMG Life Sciences “Canadian Impact Deals of the Year” Award

On September 25, WilmerHale was named as the winner of the LMG Life Sciences "Canadian Impact Deals of the Year" award at the LMG Life Sciences Awards dinner at the Essex House in New York City.

July 11, 2013

SEC Adopts JOBS Act and Dodd-Frank Act Private Placement Provisions; Proposes Additional Requirements for Private Placement Market

At an open meeting on July 10, 2013, the Securities and Exchange Commission (SEC): approved final rules implementing Section 201(a)(1) of the Jumpstart Our Business Startups Act (the JOBS Act) to eliminate the prohibition on general solicitation and advertising for certain offerings made pursuant to Rule 506 of Regulation D of the Securities Act of 1933 (the Securities Act) and Rule 144A under the Securities Act; approved a final rule to disqualify securities offerings involving certain felons and other “bad actors” from reliance on Rule 506, as mandated by Section 926 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the Dodd-Frank Act); and proposed amendments to Regulation D, Form D and Rule 156 under the Securities Act intended to enhance the SEC’s ability to evaluate changes in the market and to address the development of practices in Rule 506 offerings.